OBJECTIVES: To explore the anxiolytic effects of a 4-month randomized, placebo-controlled trial of exercise and antidepressant medication in patients with major depressive disorder (MDD), and to examine the potential modifying effects of anxiety in treating depressive symptoms. MATERIALS AND METHODS: In this secondary analysis of the SMILE-II trial, 148 sedentary adults with MDD were randomized to: (a) supervised exercise, (b) home-based exercise, (c) sertraline, or (d) placebo control. Symptoms of state anxiety measured by the Spielberger Anxiety Inventory were examined before and after 4 months of treatment. Depressive symptoms were assessed by the Hamilton Depression Rating Scale (HAMD) and Beck Depression Inventory-II (BDI-II). Analyses were carried out using general linear models. RESULTS: Compared to placebo controls, the exercise and sertraline groups had lower state anxiety scores (standardized difference = 0.3 [95% CI = -0.6, -0.04]; p = 0.02) after treatment. Higher pretreatment state anxiety was associated with poorer depression outcomes in the active treatments compared to placebo controls for both the HAMD (p = .004) and BDI-II (p = .02). CONCLUSION: Aerobic exercise as well as sertraline reduced symptoms of state anxiety in patients with MDD. Higher levels of pretreatment anxiety attenuated the effects of the interventions on depressive symptoms, however, especially among exercisers. Patients with MDD with higher comorbid state anxiety appear to be less likely to benefit from exercise interventions in reducing depression and thus may require supplemental treatment with special attention to anxiety.
OBJECTIVES: To explore the anxiolytic effects of a 4-month randomized, placebo-controlled trial of exercise and antidepressant medication in patients with major depressive disorder (MDD), and to examine the potential modifying effects of anxiety in treating depressive symptoms. MATERIALS AND METHODS: In this secondary analysis of the SMILE-II trial, 148 sedentary adults with MDD were randomized to: (a) supervised exercise, (b) home-based exercise, (c) sertraline, or (d) placebo control. Symptoms of state anxiety measured by the Spielberger Anxiety Inventory were examined before and after 4 months of treatment. Depressive symptoms were assessed by the Hamilton Depression Rating Scale (HAMD) and Beck Depression Inventory-II (BDI-II). Analyses were carried out using general linear models. RESULTS: Compared to placebo controls, the exercise and sertraline groups had lower state anxiety scores (standardized difference = 0.3 [95% CI = -0.6, -0.04]; p = 0.02) after treatment. Higher pretreatment state anxiety was associated with poorer depression outcomes in the active treatments compared to placebo controls for both the HAMD (p = .004) and BDI-II (p = .02). CONCLUSION: Aerobic exercise as well as sertraline reduced symptoms of state anxiety in patients with MDD. Higher levels of pretreatment anxiety attenuated the effects of the interventions on depressive symptoms, however, especially among exercisers. Patients with MDD with higher comorbid state anxiety appear to be less likely to benefit from exercise interventions in reducing depression and thus may require supplemental treatment with special attention to anxiety.
Authors: P D Londborg; M T Hegel; S Goldstein; D Goldstein; J M Himmelhoch; R Maddock; W M Patterson; J Rausch; G M Farfel Journal: J Clin Psychiatry Date: 2001-05 Impact factor: 4.384
Authors: M Olfson; B Fireman; M M Weissman; A C Leon; D V Sheehan; R G Kathol; C Hoven; L Farber Journal: Am J Psychiatry Date: 1997-12 Impact factor: 18.112
Authors: Pim Cuijpers; Marit Sijbrandij; Sander L Koole; Gerhard Andersson; Aartjan T Beekman; Charles F Reynolds Journal: World Psychiatry Date: 2014-02 Impact factor: 49.548
Authors: Gemma Lewis; Larisa Duffy; Anthony Ades; Rebekah Amos; Ricardo Araya; Sally Brabyn; Katherine S Button; Rachel Churchill; Catherine Derrick; Christopher Dowrick; Simon Gilbody; Christopher Fawsitt; William Hollingworth; Vivien Jones; Tony Kendrick; David Kessler; Daphne Kounali; Naila Khan; Paul Lanham; Jodi Pervin; Tim J Peters; Derek Riozzie; George Salaminios; Laura Thomas; Nicky J Welton; Nicola Wiles; Rebecca Woodhouse; Glyn Lewis Journal: Lancet Psychiatry Date: 2019-09-19 Impact factor: 27.083
Authors: Gary M Cooney; Kerry Dwan; Carolyn A Greig; Debbie A Lawlor; Jane Rimer; Fiona R Waugh; Marion McMurdo; Gillian E Mead Journal: Cochrane Database Syst Rev Date: 2013-09-12
Authors: Hannah M Malian; Patrick J Smith; Benson Hoffman; Wei Jiang; Katharine Ammerman; William E Kraus; Alan Hinderliter; Andrew Sherwood; James A Blumenthal Journal: J Cardiopulm Rehabil Prev Date: 2021-07-01 Impact factor: 3.646